methyl (R)-4-benzyl-2-(3-chlorobenzyl)piperazine-1-carboxylate | 1443434-21-6

• 分子结构分类: 有机化合物 - 有机杂环化合物 - 二嗪烷类
• 英文名称: methyl (R)-4-benzyl-2-(3-chlorobenzyl)piperazine-1-carboxylate
• CAS: 1443434-21-6
• 化学式: C₂₀H₂₃ClN₂O₂
• 分子量: 358.868
• InChiKey: NZTCUWPYFQKVKQ-LJQANCHMSA-N

计算性质

• 辛醇/水分配系数(LogP)：
  3.84
• 重原子数：
  25.0
• 可旋转键数：
  4.0
• 环数：
  3.0
• sp3杂化的碳原子比例：
  0.35
• 拓扑面积：
  32.78
• 氢给体数：
  0.0
• 氢受体数：
  3.0

反应信息

• 作为反应物：
  描述：

  methyl (R)-4-benzyl-2-(3-chlorobenzyl)piperazine-1-carboxylate 在 四磷十氧化物 、 三氯氧磷 作用下， 生成 (11aR)-2-benzyl-7-chloro-3,4,11,11a-tetrahydro-1H-pyrazino[1,2-b]isoquinolin-6-one
  参考文献：
  名称：

  Synthesis and SAR of potent and selective tetrahydropyrazinoisoquinolinone 5-HT2C receptor agonists

  摘要：

  The 5-HT2C receptor has been implicated as a critical regulator of appetite. Small molecule activation of the 5-HT2C receptor has been shown to affect food intake and regulate body weight gain in rodent models and more recently in human clinical trials. Therefore, 5-HT2C is a well validated target for anti-obesity therapy. The synthesis and structure-activity relationships of a series of novel tetrahydropyrazinoisoquinolinone 5-HT2C receptor agonists are presented. Several members of this series were identified as potent 5-HT2C receptor agonists with high functional selectivity against the 5-HT2A and 5-HT2B receptors and reduced food intake in an acute rat feeding model upon oral dosing. (c) 2013 Elsevier Ltd. All rights reserved.

  DOI：

  10.1016/j.bmcl.2013.04.061
• 作为产物：
  描述：

  (R)-1-benzyl-3-(3-chlorobenzyl)piperazine-2,5-dione 在 吡啶 、 lithium aluminium tetrahydride 作用下， 以 四氢呋喃 为溶剂， 生成 methyl (R)-4-benzyl-2-(3-chlorobenzyl)piperazine-1-carboxylate
  参考文献：
  名称：

  Synthesis and SAR of potent and selective tetrahydropyrazinoisoquinolinone 5-HT2C receptor agonists

  摘要：

  The 5-HT2C receptor has been implicated as a critical regulator of appetite. Small molecule activation of the 5-HT2C receptor has been shown to affect food intake and regulate body weight gain in rodent models and more recently in human clinical trials. Therefore, 5-HT2C is a well validated target for anti-obesity therapy. The synthesis and structure-activity relationships of a series of novel tetrahydropyrazinoisoquinolinone 5-HT2C receptor agonists are presented. Several members of this series were identified as potent 5-HT2C receptor agonists with high functional selectivity against the 5-HT2A and 5-HT2B receptors and reduced food intake in an acute rat feeding model upon oral dosing. (c) 2013 Elsevier Ltd. All rights reserved.

  DOI：

  10.1016/j.bmcl.2013.04.061